Fenofibrate and Cardiovascular Outcomes in Statin Users with Metabolic Syndrome
A propensity matched cohort study, by Kim et al. (2019), investigated fenofibrate as an add-on to statin treatment to reduce persistent cardiovascular risk in adults with metabolic syndrome in real-world settings. Results showed a significantly lower risk of major cardiovascular events compared with statin treatment alone.
Modern Medicine – Issue 4 2020
